Role of the TSPO–NOX4 axis in angiogenesis in glioblastoma

Hongxiang Jiang1,2†, Fei Li1,2†, Linzhi Cai1* and Qianxue Chen1*

1Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China, 2Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China

Objective: Angiogenesis is a pathological feature of glioblastoma. Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) is a vital source of reactive oxygen species (ROS) related to angiogenesis. However, signaling pathways correlated with the isoform oxidase are unknown. The aim of this study was to elucidate the detailed mechanism of the role of NOX4 in angiogenesis in glioblastoma.

Methods: Public datasets were searched for studies on immunohistochemistry and western blotting to evaluate NOX4 expression in glioma. The location of NOX4 expression was detected by immunofluorescence. We conducted conditional deletion of the translocator protein (TSPO) targeting the protein with the synthetic ligand XBD173 in the glioblastoma mouse model. NOX4 downregulation was conducted with the NOX4 inhibitor GLX351322, and ROS production and angiogenesis were detected in glioma tissues.

Results: Clinical samples and public datasets showed that NOX4 was upregulated and associated with the prognosis. NOX4 is mainly expressed in endothelial cells of glioblastoma. Both TSPO and NOX4 promoted angiogenesis in an ROS-dependent manner, suggesting that TSPO triggered ROS production in glioblastoma via NOX4.

Conclusion: These results showed that TSPO is an upstream target of NOX4-derived mitochondrial ROS, which is indispensable for NOX4-derived mitochondrial ROS-induced angiogenesis in glioblastoma. TSPO–NOX4 signaling could serve as a molecular target for therapeutic strategies for glioblastoma.

KEYWORDS NADPH oxidase 4, translocator protein, angiogenesis, glioblastoma, reactive oxygen species

Introduction

Glioma, a common primary tumor of the central nervous system, has various heterogeneous subregions (Bakas et al., 2017). High-grade gliomas, such as glioblastoma, have a poor prognosis and often lead to death. Despite research advancements, the treatment is limited (Gusyatiner and Hegi, 2018). Glioblastoma could cause pathologic changes in angiogenesis, thereby accelerating tumor progression, making the treatment more difficult and increasing tumor aggressiveness.
Owing to the special intratumoral heterogeneity and complex vascularization processes, various types of tumor cells regulate tumor-associated blood vessels in glioma through multiple molecular mechanisms. The tumor microenvironment consists of tumor cells and tumor-associated stroma, which could generate several types of molecular mediators to moderate angiogenesis in glioma.

High tumor microvascular density is a marker of glioblastoma and indicates a poor prognosis (Fan et al., 2019). To date, the exact regulation mechanism of angiogenesis-related factors has not been fully understood. Understanding this mechanism could yield effective treatment targets, particularly for drug intervention. Currently, altering metabolic gene expressions in tumors is the ideal therapeutic target for tumors (Liu et al., 2021). Oxidative stress plays a crucial role in cancer development and progression. Under physiological conditions, increased reactive oxygen species (ROS) production plays a key signaling function (Moloney and Cotter, 2018). Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) is a NOX family isoform correlated with ROS production and various biological functions in the development of cancer (Moloney and Cotter, 2018). NOX4-induced ROS production and increased Nox4 expression play key roles in glioma (Wu et al., 2017). However, mechanisms underlying Nox4-derived ROS levels in glioblastoma are largely unknown.

Wolf et al. (Wolf et al., 2020) showed that the translocator protein (TSPO) is a regulatory node for microglial functions in angiogenesis carried out in a NOX1-dependent manner. Since TSPO is enriched in glioma, it may be a diagnostic biomarker (Su et al., 2015). Positron emission tomography (PET) with radio-labelled TSPO ligands, such as [11C]PK11195, shows good abilities to monitor and quantify tumor progression (Su et al., 2015). Owing to the special intratumoral heterogeneity and complex vascularization processes, various types of tumor cells regulate tumor-associated blood vessels in glioma through multiple molecular mechanisms. The tumor microenvironment consists of tumor cells and tumor-associated stroma, which could generate several types of molecular mediators to moderate angiogenesis in glioma.

High tumor microvascular density is a marker of glioblastoma and indicates a poor prognosis (Fan et al., 2019). To date, the exact regulation mechanism of angiogenesis-related factors has not been fully understood. Understanding this mechanism could yield effective treatment targets, particularly for drug intervention. Currently, altering metabolic gene expressions in tumors is the ideal therapeutic target for tumors (Liu et al., 2021). Oxidative stress plays a crucial role in cancer development and progression. Under physiological conditions, increased reactive oxygen species (ROS) production plays a key signaling function (Moloney and Cotter, 2018). Nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) is a NOX family isoform correlated with ROS production and various biological functions in the development of cancer (Moloney and Cotter, 2018). NOX4-induced ROS production and increased Nox4 expression play key roles in glioma (Wu et al., 2017). However, mechanisms underlying Nox4-derived ROS levels in glioblastoma are largely unknown.

Wolf et al. (Wolf et al., 2020) showed that the translocator protein (TSPO) is a regulatory node for microglial functions in angiogenesis carried out in a NOX1-dependent manner. Since TSPO is enriched in glioma, it may be a diagnostic biomarker (Su et al., 2015). Positron emission tomography (PET) with radio-labelled TSPO ligands, such as [11C]PK11195, shows good abilities to monitor and quantify tumor progression (Su et al., 2013). Nevertheless, the function of TSPO in glioma or its potential molecular mechanism has not been fully detailed. The aim of this study was to perform a complete mechanistic analysis of NOX4-mediated TSPO-induced ROS elevation in angiogenesis in glioblastoma. The results could serve as a basis for exploring therapeutic targets based on the dual inhibition of NOX4 and TSPO in glioblastoma.

Materials and methods

Clinical samples

We obtained glioma tissues from the Department of Neurosurgery, Renmin Hospital, Wuhan University, from January 2018 to July 2021. Immunohistochemical staining was performed for 17 glioblastoma, 15 grade III malignant, 19 grade II malignant, 23 grade I malignant, and 11 healthy tumor-adjacent tissues, stored at −80°C. Supplementary Table S1 shows clinical data of all patients. Preoperatively, chemotherapy or radiotherapy was not performed in any patient. All patients provided written informed consent. The research protocol was approved by the ethics committee of Renmin Hospital, Wuhan University (approved number: WDRY2022-KS002).

Cell culture

Murine GL261 glioma cells were derived from the Tumor Cell Repository of the National Cancer Institute, Frederick, United States of America. They were cultured under adherent conditions in Dulbecco’s Modified Eagle Medium, containing 100 μg/ml penicillin, 100 μg/ml streptomycin, and 10% fetal bovine serum, at 37°C in a humidified atmosphere under 95% O2 and 5% CO2.

Tumor inoculation

C57Bl/6J mice were purchased from Shulaibao Biotechnology Co., Ltd. Animal feeding and experimental protocols of this study conformed to the guidelines set by the Animal Ethics Committee of Renmin Hospital, Wuhan University. GL261 glioma cells growing in the logarithmic phase were prepared. They were resuspended in phosphate-buffered saline (PBS) at 1×10^6 cells/100 μL and then injected subcutaneously into the brains of 6-week-old C57Bl/6J mice. A layer of moisturizing cream covered their corneas. The scalp was disinfected with 10% potassium iodide solution, and a median incision was made on it with a scalpel. The mice were then fixed on a stereotaxic frame. A 23-G needle was used to drill holes in the skull at 1.5-mm puncture points in front and on the right side of the anterior fontanelle. Further, 1 μL PBS, containing 1 × 10^7 GL261 glioblastoma cells, was slowly injected into the brain of the mouse at a depth of 3 mm, using a 22-G Hamilton syringe, over 2 min. Finally, the syringe was pulled at a rate of 1 mm/min, and the skin was sutured. In mouse cells, the tumor grew for 3 weeks.

Animal experiments

For the in vivo treatment, C57Bl/6J mice were randomly divided into treatment and control groups. In vivo experiments were performed to explore the role of NOX4 in tumorigenesis in an intracranial xenograft model. We divided all intracranial xenograft mice into three groups: treatment group 1, provided with 3.8 mg/day/kg body weight of GLX351322 (NOX4 inhibitor, reducing NOX4 expression) in normal saline served as drinking water every day for 2 weeks; treatment group 2 provided with GLX351322 in normal saline served as drinking water every day for 1 week; and control group, provided with no NOX4 inhibitor. Each group included seven C57Bl/6J mice (Figure 2A). The
intraperitoneal or gastric administration was initiated on day 7. Phenylpurine XBD173 (AC-5216, EMAPuniL) was obtained by custom-synthesis from APAC Pharmaceuticals. One week after tumor inoculation, the mice were injected intraperitoneally with XBD173 at 10 mg/kg, dissolved in dimethyl sulfoxide as carrier control. Each group included seven C57Bl/6 mice. After tumor inoculation, the C57Bl/6 status was observed daily. The dynamic weight change of each C57Bl/6 mouse was recorded weekly. To analyze survival, the mice were regularly monitored and sacrificed when they showed notable weight loss (over 20% of body weight) and/or significant neurological symptoms. The entire brain of sacrificed mice were wrapped in paraffin and preserved for further analyses. The aforementioned animal experiments were approved by the Institutional Animal Care and Use Committee of Renmin Hospital, Wuhan University.

**Mouse brain tissue preparation**

Mouse brains were collected and then fixed in 4% sucrose for 24 h at 4°C and dehydrated in 30% sucrose at 4°C for ≥24 h. Subsequently, brain tissue was placed in a frozen matrix and slowly frozen to −80°C in isopentane. Tissue samples were obtained in 40-μm horizontal sections by sectioning horizontal slides. Finally, for protection from light, floating sections were stored at −20°C with a cryoprotective agent.

**Immunohistochemistry**

The tissues were fixed with 4% paraformaldehyde, embedded in paraffin, and sectioned. After hydration, they were treated with 3% H2O2 for 10 min, blocked with 1% bovine serum albumin for 1 h, and incubated overnight with the anti-NOX4 primary antibody followed by the horseradish peroxidase-linked secondary antibody (Servicebio, China). Subsequently, they were stained with 3, 3′-diaminobenzidine and hematoxylin. Images were captured using an Olympus BX51 microscope (Olympus). The distribution and intensity of NOX4 staining (0 = negative; 1 = weak; 2 = moderate; 3 = strong; 4 = strong and widespread) were estimated by semi-quantitative scoring.

**Fluorescent immunohistochemistry and confocal microscopy**

On day 1, the floating slices were cleaned thrice with PBS with 0.1% Tween-20 (PBST), for 5 min each time. Dual Endogenous Enzyme Block Dako was used at room temperature (25°C ± 5°C) for 10 min to block endogenous peroxidase, followed by three rinses with PBST. The sections were sealed for 1 h in PBS or a protein blocking reagent in the presence of 5% normal donkey serum and 0.3% Triton-X. Finally, they were incubated overnight at 4°C with the primary antibody diluted in the Dako antibody thinner. On day 2, the sections were cleaned and incubated with secondary antibodies diluted with the Dako Antibody Diluent for 2 h at room temperature (25°C ± 5°C) before coupling with fluorophore-conjugated streptavidin. Two caps were incubated together at room temperature (25°C ± 5°C). Nuclei were stained with 2 μg/ml 4′,6-diamidino-2-phenylindole. At the end of the experiment, the sections were placed on glass slides and allowed to air-dry for 10 min. Tissues were fixed in a fluorescent mounting medium and covered. At the Bioimaging Core Facility, confocal microscopy was performed using the Leica SP8X WLL microscope equipped with the 405-nm (470–670-nm) WLL2 laser and an acousto-optic beam splitter. Images were acquired using a 63 × 1.4 objective for visualization of single-cell and subcellular structures, with an image pixel size of 80 nm. To avoid leakage, the experiments were recorded sequentially. For all experiments, imaging was performed using the appropriate settings based on normalized negative and positive groups.

**Western blotting**

The cells were washed with PBS at a low temperature (15°C ± 5°C) and lysed with radioimmunoprecipitation assay. The protein level in the supernatant was determined by the bicinchoninic acid protein assay. Further, 5% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was added into lysates, followed by boiling at 98°C for 10 min. Total protein was loaded onto SDS-PAGE and electro-transferred on 0.22-μM polyvinylidene difluoride membranes, which were incubated with anti-GAPDH, anti-NOX4, CD31, and anti-TSPO primary antibodies overnight and secondary antibodies diluted in the Dako antibody thinner. On day 2, the sections were cleaned and incubated with secondary antibodies diluted with the Dako Antibody Diluent for 2 h at room temperature (25°C ± 5°C). Nuclei were stained with 2 μg/ml 4′,6-diamidino-2-phenylindole. At the end of the experiment, the sections were placed on glass slides and allowed to air-dry for 10 min. Tissues were fixed in a fluorescent mounting medium and covered. At the Bioimaging Core Facility, confocal microscopy was performed using the Leica SP8X WLL microscope equipped with the 405-nm (470–670-nm) WLL2 laser and an acousto-optic beam splitter. Images were acquired using a 63 × 1.4 objective for visualization of single-cell and subcellular structures, with an image pixel size of 80 nm. To avoid leakage, the experiments were recorded sequentially. For all experiments, imaging was performed using the appropriate settings based on normalized negative and positive groups.

**ROS level measurement**

ROS levels were measured after XBD173 and GLX351322 treatments using the Reactive Oxygen Species Assay Kit and transfection with plasmids, following the manufacturer’s protocol. At 525 nm, cell absorbance was measured using a spectrophotometer.

**RNA extraction and quantitative real-time PCR**

RNA extraction of related genes from tissues using TRizol reagent (Invitrogen, Carlsbad, CA, United States). The RNA was then tested for purity as well as concentration. And a
reverse transcription kit was applied in the convert of whole samples to cDNA. Performing qRT-PCR by employing SYBR Green (Thermo Fisher Scientific) system. GraphPad Prism 6.0. Was used to assess statistics. The results from the experimental and control groups were compared using the relative Ct technique, with GAPDH serving as an internal reference.

Statistical analysis

Statistical analyses were performed using SPSS 19.0 and GraphPad Prism 6.0. In vitro experimental data are expressed as mean ± standard deviation. The one-way analysis of variance and the t-test were performed for between-group discrepancies. Each experiment was repeated in triplicate. A p-value < 0.05 was considered to indicate statistical significance.

Results

NOX4 overexpression and association with the prognosis of glioblastoma

RNA sequencing data from The Cancer Genome Atlas (TCGA) Glioblastoma dataset showed that the mRNA expression of NOX4 was enriched in glioblastoma compared to low-grade glioma and non-tumor tissues (Figures 1A,B). Further, the Chinese Glioma Genome Atlas (CGGA) and TCGA Low-Grade Glioma datasets showed that NOX4 expression was significantly higher in glioblastoma comparing with other histological types (Figures 1C,D). Consistent with these findings, immunohistochemistry staining and western blotting of clinical samples showed that the NOX4 protein level was higher in high-grade glioma than in low-grade glioma (Figures 1E,F). Supplementary Table S1 lists patient...
information. Regarding the prognostic value of NOX4 in glioma, the CGGA and TCGA Low-Grade Glioma datasets showed that patients with glioma with a higher NOX4 expression had worse overall survival than those with a lower NOX4 expression (Figures 1G,H). These results suggested that NOX4 was upregulated and acted as a potential oncogene in glioblastoma.

**Correlation of NOX4 with the prognosis of glioma in an intracranial xenograft model**

Survival curves showed that mice in the control group died significantly earlier than those in treatment group 1 (Figure 2B). Hematoxylin–eosin staining of brain tissues of tumour-bearing mice showed a significantly greater average volume of glioma in the control group than in the treatment groups in vivo (Figure 2C). These results suggested that NOX4 could promote glioma growth and progression, consistent with TCGA and CGGA dataset results.

**Induction of angiogenesis by Nox4 in an ROS-dependent manner**

Human brain cell-type enrichment profiles (https://cell-enrichment.shinyapps.io/Brain/) have shown that NOX4 is related to the glioblastoma-associated endothelium. Angiogenesis is common in glioblastoma and contributes to its aggressive behavior. We analyzed the correlation between angiogenesis and the NOX4 expression in glioblastoma and then performed immunofluorescent co-staining against CD31. Clinical samples of glioblastoma showed NOX4 expression in CD31-positive endothelial cells attached to the newly forming vasculature within the tumor region. Murine glioblastoma models confirmed this finding. NOX4-positive and CD31-positive endothelial cells showed a strong correlation (Figure 3A). These results suggested that NOX4 may play a vital role in angiogenesis.

Our previous findings indicated that NOX4 was mainly expressed in endothelial cells of glioblastoma, leading us to determine whether or not NOX4 regulates angiogenesis in glioma. Nox4 is a critical mediator of ROS production and tumor progression (Hsieh et al., 2012). To further determine the mechanism of NOX4 involvement in glioma, we compared ROS levels between the control and LX351322 treatment groups.

Targeting NOX4 with GLX351322 affect the ROS level (Figure 3B). We stained tissues in the control and GLX351322 treatment groups for the angiogenesis marker CD31 and performed western blotting (Figures 3C,D). The control group showed more abundant CD31 + blood vessels compared to the GLX351322 treatment group. These results indicated that NOX4 induced angiogenesis in an ROS-dependent manner in endothelial cells of glioblastoma in vivo.

**Promotion of angiogenesis in glioblastoma by TSPO in vivo**

TSPO expression in glioma is correlated with the grade of malignancy and survival. It occurs in microglia, tumor-associated macrophages, endothelial cells, and pericytes (Cai et al., 2020). We explored the role of TSPO in glioma by targeting it with the synthetic ligand XBD173.

We treated xenograft tumors of C57BL/6j mice with daily intraperitoneal injections of XBD173 for one or 2 weeks (Figure 4A). The XBD173 treatment group showed more survival benefit compared to the control group (Figure 4B). The tumor size was significantly smaller in the XBD173 treatment group compared to the control group.
These results indicated that TSPO could promote glioma growth and malignancy in vivo.

Further, we investigated the anti-angiogenic potential of XBD173. Western blotting showed more reduction of angiogenesis in the XBD173 treatment group than in the control group and successful knockdown of TSPO in the XBD173 treatment group (Figure 4D). Being a rich source of ROS, reactive mononuclear phagocytes are drivers of neurodegeneration. We analyzed if targeting TSPO with XBD173 affects ROS production of glioblastoma in vivo. The XBD173 treatment group showed lower ROS levels and number of vessels compared to the control group (Figures 4E,F). These results suggested that XBD173 attenuated both ROS production and angiogenesis.

Trigger of ROS production by TSPO via NOX4 in glioblastoma

We evaluated the molecular pathways involved in the role of TSPO in phagocyte ROS production. TSPO can regulate microglial functions in angiogenesis in an NOX1-dependent manner (Wolf et al., 2020). ROS is mainly produced by NOX and may be produced by mitochondria under certain conditions. We aimed to validate the hypothesis that TSPO regulates angiogenesis via NOX4 in glioblastoma. We performed immunofluorescent co-staining of NOX4 against Iba1.

Clinical samples of glioblastoma showed NOX4 expression in Iba1-positive microglia and macrophages (Supplementary Figure S1). We treated xenograft tumors of C57BL/6J mice with both the synthetic ligand XBD173 and GLX351322 and compared it to XBD173 or GLX351322 alone. The application of both XBD173 and GLX351322 did not yield survival benefit (Figure 5A). The average tumor size of the combined XBD173 and GLX351322 group was significantly smaller than that of the XBD173 or GLX351322 group (Figure 5B). Additionally, the ROS level and angiogenesis were reduced in the combined XBD173 and GLX351322 group compared to the XBD173 or GLX351322 group (Figures 5C–F). These results suggested that NOX4 in endothelial cells plays a key role in ROS production in glioblastoma and critically depends on TSPO in microglia.

Discussion

In recent decades, great progress has been made in tumor research. Glioma is a common malignant brain tumor characterized by abnormal angiogenesis and metabolism. In its pathological progression, metabolic abnormalities interact with angiogenesis (Krisha et al., 2021). Cellular metabolism can produce and accumulate abundant extracellular ROS (Li et al., 2020). Nevertheless, aerobic cells and tissues are imbalanced because of excessive accumulation of extracellular...
ROS, or “oxidative stress,” which is associated with tumor progression (Miller, 2009). In many pathophysiological processes, both extracellular and intracellular ROS are related to angiogenesis (Siciliano et al., 2020). Intracellular ROS plays an important role via vascular endothelial growth factor (VEGF) signaling in endothelial cells (Zheng et al., 2021). The NOX family is a plasma membrane-binding enzyme that produces superoxides and is the main source of ROS in the tumor microenvironment (Ohgaki and Kleihues, 2013).

In this study, NOX4 expression was analyzed in glioma samples from patients and mouse models. The results indicated that NOX4 is mainly distributed in endothelial cells and can affect angiogenesis in glioma. Furthermore, we investigated the effect of NOX4 on angiogenesis in glioma and progression in an in vivo tumor model using the NOX4 inhibitor GLX351322. The NOX family, which includes NOX1, NOX2, NOX3, NOX4, and NOX5 subtypes, is a key mediator of cyclic hypoxia-mediated ROS production and tumor progression (Cicone et al., 2019). Excessive ROS production by NOXs leads to oxidative stress and tumor progression (Zhai et al., 2020). NOXs perform multiple functions in tumors, such as proliferation, angiogenesis, anti-apoptosis, epithelial–mesenchymal transition, glycolysis, and metastasis (Lamantia et al., 2014; Lakshmanachetty et al., 2021). They may be closely related to the inflammatory tumor microenvironment, in which oxidants act as positive signaling mediators for tumor growth (Guadagno et al., 2018). Nevertheless, the relationship between the tumor microenvironment and NOXs remains unclear. In our study, ROS production in glioma was strongly regulated by Nox4.

TSPO is a powerful and precise biomarker of microglial activation in neurodegenerative diseases (Ding et al., 2014). It is elevated on PET in Alzheimer’s disease, mild cognitive impairment (Iwata et al., 2020), and almost all types of central nervous system pathologies and reduced in some psychiatric disorders, such as schizophrenia (Rossi et al., 1988). It is expressed in tumor cells and microenvironments, particularly in tumor-associated myeloid cells, pericytes, and endothelial cells. Its expression in glioblastoma tumor tissue or possible mechanism remains unclear. In addition, PET using the TSPO radiation ligand is not a standard imaging modality for patients with brain tumors (Zhang et al., 2020; Yang T. et al., 2021; Holzl et al., 2021). The relationship between CD31+ and TSPO+ endothelial cells is found in blood vessels of different sizes, including capillaries (Huang et al., 2019). The presence of TSPO+ blood vessels in the brain of any disease suggests that endothelial TSPO may be constructive (Duan et al., 2019). This finding is associated with the binding and distribution of TSPO ligands in the brain parenchyma (Duan et al., 2019). In this study, targeting the specific ligand XBD173 showed that the TSPO signaling pathway played a key role in reducing angiogenesis in glioblastoma.
consistent with the main pathological features of neovascular age-related macular degeneration. We hypothesized that TSPO plays a critical role in NOX4-mediated extracellular ROS production in glioblastoma. A TSPO-dependent regulation of NOX enzymes has been proposed (Wierstra et al., 2019; Yang Z. et al., 2021). Microglia produce extracellular ROS via NOX1. TSPO is involved in the production of mitochondrial ROS in relation to cell signal transduction (Venkatesh et al., 2019). Therefore, we investigated the role of TSPO in subsequent NOX4-derived ROS generation in glioblastoma. ROS was significantly reduced in TSPO-deficient glioblastoma. NOX2 is the main source of ROS in phagocytes (Hamerlik et al., 2012); however, NOX1-and NOX4-dependent ROS productions may occur in microglia of different neurological diseases (Acharya et al., 2016; Blanchart et al., 2017). Although only a few in vivo studies have investigated the role of NOX2 or NOX4 in deficient mice (Hamerlik et al., 2012; Feng et al., 2018), most studies on microglia have been conducted using cell lines. In this study, TSPO-mediated angiogenesis was blocked by XBD173, which inhibited Nox4 expression and the production of acute NOX4-derived ROS after stimulation. Therefore, these signal cascades in angiogenesis should be identified in future studies. In addition, botanical drugs targeting TSPO-NOX4 axis have shown great potential in the treatment of glioblastoma, such as paeoniflorin, which will be further studied in the later stage.

This study has some limitations. First, targeting or knocking-out TSPO by synthesizing the ligand XBD173 confirmed that TSPO could inhibit phagocytic reactivity in the laser-induced mouse neovascular age-related macular degeneration model. However, we only analyzed the effect of TSPO using XBD173. The synthetic ligand XBD173 is a fat-soluble reagent and, therefore, easily crosses the blood–brain barrier, thus becoming a potential substitute of brain tumor chemotherapy in clinical practice. Therefore, the exact composition and function of these TSPO proteins in glioma should be further explored. Second, GLX351322 knocked-out and chemically inhibited the NOX4 enzyme. Although often referred to as specific NOX4 inhibitors, these substances exhibit many undergo side reactions with questionable specificity (Radoul et al., 2021). Further studies are required in this direction. In addition, XBD173 reduces the
expression of angiogenic factors and choroidal neovascularization by regulating phagocytes. Although Ang1, Ang2, and Vegf were expressed by phagocytes in vivo, only VEGF was generated and secreted by stimulated microglia. The specific interactions between phagocytes and endothelial cells and other related signaling pathways that may play a role in angiogenesis in glioma should be further investigated.

**Conclusion**

In this study, both TSPO and NOX4 promoted angiogenesis in glioblastoma. This was the first study to demonstrate that TSPO was the upstream target of NOX4-derived mitochondrial ROS, necessary for NOX4-derived mitochondrial ROS-induced angiogenesis in glioblastoma (Figure 6). TSPO–NOX4 signaling seems to be a promising molecular therapeutic target for glioblastoma.

**Data availability statement**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**Ethics statement**

All patients provided written informed consent. The research protocol was approved by the ethics committee of Renmin10 Hospital, Wuhan University (approved number: WDRY2022-KS002).

**Author contributions**

This manuscript represents original work and has derived from the effort of all the contributing authors. All of them have contributed significantly and are in agreement with the content of the manuscript. QC and LC have contributed to study conception and design. HJ and LF have contributed to result interpretation and manuscript drafting. HJ has contributed to the IHC experiments and statistical analysis. HJ and FL have contributed to interpretation of the study results and critical revision for important intellectual contents. All authors read and approved the final manuscript.

**Funding**

This work was supported by the National Natural Science Foundation of China (No. 82071299).

**Conflict of interest**

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s note**

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Supplementary material**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.1001588/full#supplementary-material
References

Acharya, M. M., Green, K. N., Allen, B. D., Najafi, A. R., Syage, A., Minasyan, H., et al. (2016). Elimination of microglia improves cognitive function following cranial irradiation. Sci. Rep. 6, 35145. doi:10.1038/srep35145

Bakas, S., Alkhat, H., Sotiras, A., Bilillo, M., Ruyczyk, M., Kirby, J. S., et al. (2017). Advancing the Cancer Genome Atlas glioma MRI collections with expert segmentation: labels and radiomic features. Sci. Data 4, 170017. doi:10.1038/sdata.2017.17

Blanchart, A., Fernando, R., Haring, M., Assaife-Lopes, N., Romanov, R. A., Andang, M., et al. (2017). Endogenous GABAA receptor activity suppresses glioma growth. Oncogene 36 (6), 777–786. doi:10.1038/onc.2016.245

Cai, L., Kircheitner, S. V., Zhao, D., Li, M., Tonn, J. C., Glass, R., et al. (2020). Glioblastoma exhibits inter-individual heterogeneity of TSPO and LAT1 expression in neoplastic and parenchymal cells. Int. J. Mol. Sci. 21 (2), E612. doi:10.3390/ijms21020612

Cicone, F., Cardillo, L., Scaringi, C., Arcella, A., Giangaspero, F., Scipioni, F., et al. (2019). (18 F-DOPA uptake does not correlate with IDH mutation status and lp/19q co-deletion in glioma. Ann. Nucl. Med. 33 (4), 295–302. doi:10.1007/s12149-018-01328-3

Ding, P., Wang, W., Wang, J., Yang, Z., and Xue, L. (2014). Expression of tumor-associated macrophage in progression of human glioma. Cell biochem. Biophys. 58, 1635–1631. doi:10.1007/s12013-014-01033-1

Duan, X., Chan, C., and Lin, W. (2019). Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 58 (3), 670–680. doi:10.1002/anie.201804882

Fan, C., Zhang, J., Liu, Z., He, M., Kang, C., Tu, D., et al. (2019). Prognostic role of microvesSEL density in patients with glioma. Med. Biolim. 98 (9), e1695. doi:10.1097/MDB.0000000000001695

Feng, X., Liu, S., Chen, D., Roui, S., and Gupta, N. (2018). Rescue of cognitive function following fractionated brain irradiation in a novel preclinical glioma model. Elife 7, e38865. doi:10.7554/eLife.38865

Guadagno, E., Presta, I., Maisano, D., Pineta, A. C., Cardillo, G., et al. (2018). Role of macrophages in brain tumor growth and progression. Int. J. Mol. Sci. 19 (4), E1005. doi:10.3390/ijms19041005

Guayatiner, O., and Hegi, M. E. (2018). Glioma epigenetics: From subclassification to novel treatment options. Semin. Cancer Biol. 51, 50–58. doi:10.1016/j.semcancer.2017.11.010

Hamfelt, P., Lutha, J. D., Rasmussen, R., Wu, Q., Barkova, J., Lee, M., et al. (2012). Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J. Exp. Med. 209 (3), 507–520. doi:10.1084/jem.20111142

Hold, D., Hutawer, G., Zellinger, B., Schlicker, H. U., Schwartz, C., Winkler, P. A., et al. (2021). Integrated analysis of programmed cell death ligand 1 expression and safety of apremilast, a case report. Front. Oncol. 10, 597445. doi:10.3389/onc.2020.597445

Su, Z., Herholz, K., Gerhard, A., Roncaroli, F., Duleiss, D., Jackson, A., et al. (2013). [C]RJPK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. Eur. J. Nucl. Med. Mol. Imaging 40 (9), 1406–1419. doi:10.1007/s00259-013-2447-2

Liu, H., Xing, R., Ou, Z., Zhao, J., Hong, G., Zhao, T., et al. (2021). G-protein-coupled receptor GPR17 inhibits glioma development by increasing polycarb repressive complex 1-mediated ROS production. Cell Death Dis. 12 (6), 610. doi:10.1038/s41419-021-03897-0

Miller, G. (2009). Brain cancer. A viral link to glioblastoma? Science 323 (5910), 30. doi:10.1126/science.323.5910.30

Meloney, J. N., and Cotter, T. G. (2018). ROS signaling in the biology of cancer. Semin. Cell Dev. Biol. 80, 56–64. doi:10.1016/j.semcdb.2017.05.023

Olhagi, K., and Khleue, P. (2013). The definition of primary and secondary glioblastoma. Clin. Cancer Res. 19 (4), 764–772. doi:10.1158/1078-0432.CCR-12-3002

Radoul, M., Hong, D., Gillespie, A. M., Najac, C., Viswanath, P., Pieter, R. O., et al. (2021). Early noninvasive metabolic biomarkers of mutant IDH inhibition in glioma. Metabolites 11 (2), 109. doi:10.3390/metabo11020109

Rossi, M. A., Garramone, A., and Dianzani, M. U. (1988). Stimulation of phosphodiesterase C activity by 4-hydroxynonenal, influence of GTP and calcium concentration. Int. J. Tissue React. 10 (5), 321–325.

Sciabino, M. A., Dastoli, S., d’Apitolio, M., Staropoli, N., Tassone, P., Tagliuffetti, P., et al. (2020). Pemolozulbimduced potssiosis in metstasic metastatic melanoma: Activity and safety of apramistol a case report. Front. Oncol. 10, 597445. doi:10.3389/onc.2020.597445

Yang, Z., Wei, L., Ye, M., Kang, C., and You, H. (2020). Treatment progress of glioblastoma. Front. Immunol. 11, 2709. doi:10.3389/fimmu.2020.02721

Yang, T., Kong, Z., and Ma, W. (2021a). PD-1/PD-1 immune checkpoint inhibitors in glioblastoma clinical studies, challenges and potential. Hum. Vaccin. Immunother. 17 (2), 546–553. doi:10.1080/21645515.2020.1782692

Zhao, Z., Wei, L., Ye, M., Kang, C., and You, H. (2020). Treatment progress of glioblastoma. Cell Death Dis. 12 (1), 51. doi:10.1038/s41419-020-03294-z

Zhai, Y., Li, G., Li, R., Chang, Y., Feng, Y., Wang, D., et al. (2020). Single-cell ow-induced metabolic reprogramming in human and porcine vascular endothelium. Elife 6, e25217. doi:10.7554/elife.25217

Yang, T., Kong, Z., and Ma, W. (2021b). PD-1/PD-1 immune checkpoint inhibitors in glioblastoma clinical studies, challenges and potential. Hum. Vaccin. Immunother. 17 (2), 546–553. doi:10.1080/21645515.2020.1782692

Zheng, Z., Zhang, X., Liu, J., He, P., Zhang, S., Zhang, Y., et al. (2021). GABAergic synapses suppress intestinal innate immunity via insulin signaling in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 118 (20), 202106311. doi:10.1073/pnas.202106311